Men with prostate cancer may be spared radiotherapy after surgery, according to late-breaking results of the RADICALS-RT trial presented by Parker et al at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA49_PR). The study answers a long-standing question about whether the benefits of radiotherapy after surgery outweigh the side effects.
RADICALS-RT (NCT00541047) is the largest ever trial of postoperative radiotherapy in prostate cancer. It found no difference in disease recurrence at 5 years between men who routinely had radiotherapy shortly after surgery and men who had radiotherapy later, if the cancer came back.
The trial enrolled 1,396 patients after surgery for prostate cancer from the UK, Denmark, Canada, and Ireland. Men were randomly allocated to postoperative radiotherapy or the standard approach of observation only, with radiotherapy kept as an option if the disease recurred.
At a median follow-up of 5 years, progression-free survival was 85% in the radiotherapy group and 88% in the standard care group (hazard ratio [HR] = 1.10; 95% confidence interval [CI] = 0.81–1.49; P = .56).
Self-reported urinary incontinence was worse at 1 year in 5.3% of patients receiving radiotherapy compared to 2.7% who had standard care (P = .008). Radiation Therapy Oncology Group (RTOG) grade 3/4 urethral stricture was reported at any time in 8% vs 5% of the radiotherapy and standard care groups, respectively (P = .03). Longer follow-up is needed to report on survival and on the primary outcome of freedom from distant metastases.
Study first author Chris Parker, MD, of The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, said, “The results suggest that radiotherapy is equally effective whether it is given to all men shortly after surgery or given later to those men with recurrent disease. There is a strong case now that observation should be the standard approach after surgery and radiotherapy should only be used if the cancer comes back.”
“The good news is that in future, many men will avoid the side effects of radiotherapy,” added Dr. Parker. “These include urinary leakage and narrowing of the urethra, which can make urination difficult. Both are potential complications after surgery alone, but the risk is increased if radiotherapy is used as well.”
The findings were confirmed in a collaborative meta-analysis, also presented at the ESMO Congress 2019, combining results of RADICALS with two similar trials, RAVES and GETUG-AFU17 (Abstract LBA48_PR).
The ARTISTIC collaboration meta-analysis included three randomized trials comparing adjuvant radiotherapy with early salvage radiotherapy following prostatectomy for men with localized prostate cancer: RADICALS (ISRCTN40814031), GETUG-AFU 17 (NCT00667069), and RAVES (NCT00860652). The analysis was planned before the results of the trials were known.
The results are based on all 2,151 men included in the 3 trials, of whom 1,074 were randomized to adjuvant radiotherapy and 1,077 men were randomized to early salvage radiotherapy; of those, 395 men (37%) have commenced salvage treatment to date.
The analysis found no evidence that adjuvant radiotherapy improves event-free survival compared to early salvage radiotherapy (HR = 1.09; 95% CI = 0.86–1.39;P = .47). Based on these results, the difference in 5-year event-free survival is likely only to be around 1%.
Author of the analysis, Claire Vale, PhD, of MRC Clinical Trials Unit, University College London, said: “Results of the ARTISTIC meta-analysis confirm those of RADICALS and provide greater evidence to support the routine use of observation and early salvage radiotherapy.”
“The meta-analysis provides the best opportunity to assess whether adjuvant radiotherapy may still have a role in some groups of men, and to investigate longer term outcomes,” added Dr. Vale.
Commenting on the data, Xavier Maldonado, MD, of Hospital Universitari Vall d’Hebron, Barcelona, said: “These are the first results to suggest that postoperative radiotherapy for prostate cancer could be omitted or delayed in some patients. This will shorten the duration of treatment for these patients and allow better use of resources since today’s radiotherapy is technically sophisticated and therefore expensive. However, strict follow-up will be needed to identify patients requiring salvage radiotherapy.”
Dr. Maldonado noted that longer follow-up is needed for the main endpoint of RADICALS-RT, which is freedom from distant metastases at 10 years, and to comprehensively report on toxicities.
Regarding the need for future research, Dr. Maldonado said the focus should be pinpointing which patients still require adjuvant radiotherapy to avoid a very early local relapse and potential subsequent metastases. “We need to develop genomic classifiers to help decide the best management strategy for each patient—whether it should include surgery and/or radiotherapy, and at which time points,” he said. ■
DISCLOSURE: The RADICALS-RT trial received funding from Cancer Research UK, MRC Clinical Trials Unit at UCL, and Canadian Cancer Trials Group. The ARTISTIC meta-analysis received funding from UK Medical Research Council. For full disclosures of the study authors, visit esmo.org.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.